Abstract
BM 06.022 is a tissue-type plasminogen activator deletion variant that is comprised of the kringle 2 and the protease domain of the native molecule. BM 06.022 is expressed as inactive inclusion bodies inE. coli and transferred into the active enzyme by an in vitro folding process. Active site labeling with dansyl-glutamyl-glycyl-arginyl chloromethyl ketone provides evidence that the purified BM 06.022 is fully active and that misfolded species are completely removed by affinity chromatography on ETI-Sepharose. The comparison of the kinetics of the inhibition of BM 06.022 with that of CHO-t-PA indicates that the active centers of both enzymes are rather similar. The further evaluation of the site of interaction of BM 06.022 and DnsEGRck by mass spectroscopy and amino acid sequence analysis revealed that the inhibitor is bound selectively to His322, which is part of the catalytic triad of this serine protease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- CHO-t-PA:
-
recombinant tissue-type plasminogen activator from transformed Chinese hamster ovary cells
- DnsEGRck:
-
dansyl-glutamyl-glycyl-arginyl chloromethyl ketone
- MUGB:
-
4-methylumbelliferyl-p-guanidino benzoate
References
Kohnert, U., Rudolph, R., Verheijen, J. H., Weening-Verhoeff, E. J. D., Stern, A., Opitz, U., Martin, U., Lill, H., Prinz, H., Lechner, M., Kresse, G.B., Buckel, P., and Fischer, S. (1992),Prot. Eng. 5, 93–100.
Pennica, D., Holmes, W. E., Kohr, W. J., Harkins, R. N., Vehar, G. A., Ward, C. A., Bennett, W. F., Yelverton, E., Seeburg, P. H., Heynecker, H. L., and Goeddel, D. V. (1983),Nature 301, 214–221.
Müller, M., Haerer, W., Ellbrück, D., Martin, U., König, R., and Seifried, E. (1992),Fibrinolysis 6, 26, Suppl. 2.
Neuhaus, K.-L., v. Essen, R., Vogt, A., König, R., Rieb, M., Appel, K.-F., and Meyer-Sabellek, W. (1991),Circulation 84, Abstr. 2275, Suppl. 4.
Higgins, D. L. and Lamb, M. C. (1986),Arch. Biochem. Biophys. 249, 418–426.
Macartney, H. W. and Menhardt, J. (1989), European Patent Application 302503.
Kruithof, E. K. O., Schleuning, W.-D., and Bachmann, F. (1985),Biochem. J. 226, 631–636.
Kitz, R. and Wilson, I. B. (1962),J. Biol. Chem. 237, 3245–3249.
Rudolph, R. (1990), inModern Methods in Protein and Nucleic Acid Research, (Tschesche, H., ed.), Walter de Gruyter, Berlin, pp. 149–171.
Urano, T., Urano, S., and Castellino, F. J. (1988),Biochem. Biophys. Res. Commun. 150, 45–51.
Smith, R. A. G. (1986),Biochem. J. 239, 477–479.
Stürzebecher, J., Neumann, U., Kohnert, U., Kresse, G. B., and Fischer, S. (1992),Protein Sci. l, 1007–1013.
Binder, B. R., Spragg, J., and Austen, K. F. (1979),J. Biol. Chem. 254, 1998–2003.
Blow, D. M. and Steitz, D. A. (1970),Ann. Rev. Biochem. 39, 63–100.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kohnert, U., Wozny, M., Llinas, M. et al. Active site labeling with dansyl-glutamyl-glycyl-arginyl chloromethyl ketone demonstrates the full activity of the refolded and purified tissue-type plasminogen activator variant BM 06.022. Appl Biochem Biotechnol 55, 157–166 (1995). https://doi.org/10.1007/BF02783556
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02783556